FHTX
Foghorn Therapeutics Inc
2.00$
+0.5%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Cash Flow
Foghorn Therapeutics Inc (FHTX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -19 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 17 | Q1 18 | Q2 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.7 | -5.7 | -5.7 | -12 | -10 | -10 | -12 | -13 | -11 | -13 | 2.7 | -11 | -23 | -18 | -21 | 12 | 272 | -29 | -20 | -29 | -31 | -32 | -27 | -28 | -29 | -26 | -21 | -25 | -24 | -21 | -19 | -22 | -25 | -19 | -85 | |
| 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 | 0.2 | 0.2 | 0.3 | 0.3 | 0.3 | 0.6 | 0.8 | 0.8 | 0.9 | 0.8 | 1.9 | 2.0 | 1.1 | 2.9 | 0.9 | 2.2 | 0.9 | 0.9 | 0.8 | 0.8 | 0.7 | 0.8 | 0.8 | 0.9 | 0.9 | 0.9 | 0.2 | 0.2 | 2.2 | |
| – | 0.2 | 0.2 | – | 0.3 | 0.3 | 0.4 | 0.6 | 0.5 | 0.5 | 0.9 | 1.1 | 1.9 | 2.0 | 2.4 | 2.1 | 3.2 | 3.5 | 3.8 | 3.8 | 4.6 | 4.5 | 4.1 | 3.1 | 3.2 | 3.2 | 3.0 | 2.5 | 2.7 | 2.7 | 2.7 | 2.2 | 2.4 | 2.6 | 9.9 | |
| – | – | – | – | – | – | 0.8 | 0.8 | 1.2 | 1.4 | 2.4 | 2.3 | 3.0 | 3.2 | 2.5 | 3.4 | 3.2 | 3.4 | 3.6 | 5.3 | 4.6 | 4.5 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.6 | 0.3 | 0.3 | 4.2 | -0.4 | -0.4 | -0.1 | 1.0 | 1.7 | 1.3 | 18 | 7.3 | -4.0 | 0.6 | 1.1 | 36 | 293 | -6.8 | 1.3 | -6.2 | -6.6 | -8.6 | -18 | -8.2 | -9.3 | -9.7 | -5.2 | -8.1 | -9.3 | -7.7 | -6.9 | -8.2 | -8.2 | 7.1 | -16 | |
| 0.4 | 0.4 | 0.4 | 0.2 | 0.4 | 0.4 | 0.0 | 0.1 | 1.0 | 2.2 | 5.4 | 7.5 | 1.8 | 1.2 | 0.2 | 0.1 | 0.2 | 0.4 | 0.3 | 0.3 | 0.6 | 0.5 | 0.1 | 0.0 | 0.1 | 0.0 | 0.3 | 0.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | |
| – | -0.4 | -0.4 | – | -0.4 | -0.4 | 0.0 | -0.1 | -1.0 | -2.2 | -5.4 | -100 | -3.3 | 77 | -47 | 9.7 | -159 | -124 | 46 | -6.5 | 30 | 39 | 38 | 37 | 27 | -18 | -61 | 22 | 29 | 34 | 36 | 13 | -18 | -3.0 | 28 | |
| – | – | – | – | – | – | – | – | – | – | – | – | 0.1 | 0.1 | 0.5 | 43 | 0.4 | 43 | – | – | 0.1 | 0.1 | – | – | – | – | – | – | – | – | – | – | – | -50 | – | |
| – | – | – | – | – | – | -0.5 | 4.0 | -0.5 | -0.5 | -0.5 | 4.8 | -21 | -21 | -21 | -21 | – | -21 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -0.2 | -0.2 | – | 7.7 | 7.7 | 0.1 | 8.5 | 0.2 | 48 | 41 | 129 | 0.1 | 0.1 | 0.5 | 22 | 0.4 | 1.0 | 0.3 | 0.0 | 0.1 | 0.1 | 1.4 | 0.2 | 1.2 | 103 | 1.1 | 0.0 | 0.1 | 0.3 | 0.0 | 0.6 | 50 | -50 | 0.6 | |
| 6.9 | 6.9 | 6.9 | -5.8 | -3.2 | -3.2 | -12 | -4.8 | -12 | 33 | 38 | 18 | -26 | 59 | -67 | 43 | 113 | -152 | 26 | -35 | -1.6 | 7.1 | 13 | 10 | -1.1 | 60 | -81 | -2.2 | 5.6 | 13 | 17 | -8.5 | 6.8 | -72 | -57 | |
| -6.0 | -6.0 | -6.0 | -12 | -11 | -11 | -12 | -13 | -12 | -15 | -2.7 | -18 | -25 | -20 | -21 | 12 | 271 | -29 | -20 | -29 | -32 | -33 | -27 | -28 | -29 | -26 | -21 | -25 | -24 | -21 | -19 | -22 | -25 | -19 | -85 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.